Lali Galimovna Babicheva

Lali Galimovna Babicheva

Auto-generated profile, based on publicly available information

Lali Galimovna Babicheva

Russian Medical Academy of Continuous Professional Education

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
IPIrina V. Poddubnaya
Irina V. Poddubnaya
LBLali G. Babicheva
Lali G. Babicheva
Background. Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of hematological malignancies, the vast majority of which are B-cell tumors. The most common variant of NHL is diffuse large B-cell lymphoma (DLBCL), characterized by an aggressive course, which accounts for 30–40% of all NHL. The second most common is follicular lymphoma (FL), traditionally classified as an indolent variant accounting for up to 25% of all NHL. Current therapies for these lymphoproliferative disorders which includes innovative drugs in the 1st line of therapy (LT) have demonstrated high efficacy. However, some patients develop a relapse or a refractory disease. Despite recent significant progress in the development and implementation of innovative targeted drugs, in most cases, it is not possible to achieve persistent long-term remissions after disease relapse, which leaves patients with an unmet need for effective and well-tolerated treatment options. Aim. To obtain objective data on the incidence, clinical course, and effectiveness of therapy for the most common variants of NHL in real-world practice in Russia. Materials and methods. From February to March 2023, 130 hematologists and oncologists from 30 regions of Russia were surveyed to update the data on DLBCL and FL. Results. Over the past 12 months, 5,689 patients with NHL were observed, of which 56% had DLBCL; 62% of them received the 1st LT, 22% received the 2nd LT, 10% received the 3rd LT, and only a few reached later lines. Analysis of the administered treatment options in the 2nd and 3rd LTs shows that there is no standard of care for this population, and the effectiveness of the regimens used in real-world Russian practice is extremely low. FL accounted for 23% of all 5,689 patients with NHL, of which 56% were newly diagnosed and 44% received treatment for relapse. The majority of patients with FL who received ≥3 LTs had an inferior prognosis and rapid disease progression: the median time from diagnosis to the beginning of the 3rd LT was only 26.4 months. The analysis of treatment options for patients with relapsed FL indicates a lack of standard and effective therapies. Conclusion. Relapsed and refractory DLBCL and FL represent a complex clinical situation where the main goal of treatment is disease control due to the impossibility of achieving stable remissions with existing treatment options. Clinicians with great hope are looking to the emergence of new classes of drugs that will be able to improve the prognosis for this complex population.

30 June 2020 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
LBLali G. Babicheva
Lali G. Babicheva
IPIrina V. Poddubnaya
Irina V. Poddubnaya
The aim is to evaluate the efficacy of the first-line rituximab-containing therapy of B-cell lymphoproliferative diseases in Russian clinical practice between 2014 and 2017. Materials and methods. In the post-authorisation multicenter study EQUILIBRIUM were included 1 thousand patients aged from 21 to 91 with B-cell non-Hodgkins lymphoma or chronic lymphatic leukemia who had received at least 4 cycles of rituximab-containing therapy using the drug Acellbia. This article was devoted to the group of indolent non-Hodgkins lymphomas and included 253 patients: follicular lymphoma 51% of cases, marginal zone lymphoma 44% of patients, extremely rare were registered lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia in 3% and in 2% of cases, respectively. The median age in patients with indolent non-Hodgkins lymphomas was 62 years (2191 years). The vast majority of patients were diagnosed with stage IIIIV 190 (75%) of patients. More than 1/2 (53.4%) of patients in routine practice received R-CHOP therapy as a first-line. BR regimen was applied in 15.4% of cases, 14.2% of patients were treated with R-CVP/R-COP. We indicated rare use of rituximab as monotherapy in induction mode only 4.4% of patients. And 2.4% of patients were treated with fludarabine-containing therapy. Results. The final assessment of the effect was carried out after 68 cycles of treatment and as a result the overall effect was more than 90%: the frequency of complete remission was 61%, partial responses 32.9%. The progression admitted only in 17 (6.7%) patients among 253 observed. With a median of 15 months, the median of overall survival and event-free survival was not achieved. Conclusion. The use of the available and appropriate treatment according to the domestic clinical guidelines with the inclusion of the Russian biosimilar anti-CD20 monoclonal antibody Acellbia, demonstrates high direct efficacy and satisfactory long-term treatment results comparable to the retrospective analysis of the previous clinical studies of the original drug rituximab.

10 August 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
LBLali G. Babicheva
Lali G. Babicheva
IPIrina V. Poddubnaya
Irina V. Poddubnaya
Diffuse large B-cell lymphoma (DLBCL) is the most common variant of non-Hodgkin's lymphoma and accounts for about 1/3 of all non-Hodgkin's lymphomas in Western countries and about 40% of B-cell tumors worldwide. Correct diagnosis of clinically distinct subgroups of aggressive mature B-cell lymphomas is crucial for the choice of adequate treatment. Currently, the identification of DLBCL subtype depends on a combination of morphologic, immunophenotypic, and cytogenetic/molecular features. The classification covers the most common unspecified variant of DLBCL, also referred to as "not otherwise specified" (NOS), and a number of other rare forms. Over the past two decades, DLBCL NOS which accounts for more than 80% of all cases, has been the subject of a growing number of molecular studies that have identified prognostic factors that are being actively introduced into real-world clinical practice. Only the integration of morphological, immunohistochemical and molecular features of DLBCL will lead to the achievement of the long-term goal of curing the majority of patients with minimal or no toxic manifestations with the aid of personalized healthcare.

30 November 2020 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
IPI. V. Poddubnaya
I. V. Poddubnaya
GTG. S. Tumian
G. S. Tumian
OTO. P. Trofimova
O. P. Trofimova
LBL. G. Babicheva
L. G. Babicheva
EBE. A. Bariakh
E. A. Bariakh
APA. S. Poliakov
A. S. Poliakov
Features of management of oncohematological patients in the context of the COVID-19 pandemic. Lecture

10 December 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
IPIrina V. Poddubnaya
Irina V. Poddubnaya
LBLali G. Babicheva
Lali G. Babicheva
EBElena A. Bariakh
Elena A. Bariakh
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous orphan lymphoproliferative disease with an aggressive course, which accounts for 30–40% of all non-Hodgkin lymphomas. Approximately 3,000 new cases of DLBCL are diagnosed annually in Russia. The trend towards a steady increase in DLBCL incidence worldwide and the rapidly changing treatment landscape with the introduction of innovative options require the updating of epidemiological data. Despite a deeper understanding of the lymphomagenesis and molecular heterogeneity of DLBCL, the R-CHOP regimen remains the first-line standard of care for the vast majority (74%) of patients in Russia and worldwide. The effectiveness of this approach varies greatly and depends on several clinical, biological, and genetic factors. Currently, the most effective and simple prognostic model is the International Prognostic Index (IPI), according to which approximately 20% of patients are at intermediate/high risk of early progression (IPI3-5) and require therapy modification. After the first-line standard immunochemotherapy, 60–70% of DLBCL patients achieve long-term remission with the potential for cure. However, the occurrence of relapse or refractory disease in the remaining 40% of patients is associated with an abysmal prognosis with a median overall survival of about 6 months, which tends to decrease with each subsequent line, warranting an urgent need for new innovative treatments for patients with relapsed DLBCL.

30 June 2020 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
LBLali G. Babicheva
Lali G. Babicheva
IPIrina V. Poddubnaya
Irina V. Poddubnaya
Actuality. The inability of a persons immune system to withstand foreign antigenic aggression is called immunodeficiency. More than 1/2 of all cases of secondary immunodeficiency (SID) in the world are occupied by hemoblastosis and, in a greater degree, the therapy, accompanied by the immunosuppression. Due to the expansion of the arsenal of new targeted drugs for the treatment of oncohematological diseases affecting different parts of the immune system, to increasingly frequent use of autologous and especially allogeneic hematopoietic cell transplantation, the prevalence and the frequency of SID are inexorably increasing. Timely diagnosis of SID should be the starting point of the management of oncohematological patients to reduce the incidence of infectious complications and, as a result, case fatality rate. Monitoring is based on assessing risk factors and identifying the category of patients requiring active preventive measures before they develop severe infection. Elimination of the main cause of SID development is the preferred option for the prevention of the infectious complications. However, in case of multiple myeloma, chronic lymphocytic leukemia and other oncohematological diseases, this option is often impossible. Therefore, active accompanying therapy is necessary for this category of patients, in particular immunoglobulin (Ig) replacement therapy. Main clinical communities are currently in the process of updating their guidelines and recommendations on using Ig replacement therapy in patients with hemoblastosis accompanied severe recurrent infections; after ineffective antibiotic treatment; with a proven inadequate specific antibody response; IgG4 g/l. Numerous cohort, observational and randomized trials showed the significant reduction in the number of infectious complications in oncohematological patients on using long-term (not less than 1012 months) intravenous Ig replacement therapy. The lack of attention of oncologists and hematologists to the early diagnosis and prevention of these conditions leads to the increase in the number of infectious complications with all the consequences such as worsen treatment results and increase mortality among oncohematological patients. Conclusion. There is a real need to raise awareness among physicians and patients, to use screening and better management of the group of patients with increased risk of SID, and preventive use of intravenous Ig to reduce the incidence of infectious complications and active accompanying therapy aimed at reducing infection-related mortality.